Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

National Cancer Center (NCC)

Status

Active, not recruiting

Conditions

Pancreas Adenocarcinoma

Study type

Observational

Funder types

Other

Identifiers

NCC2019-0027

Details and patient eligibility

About

This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

Full description

Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.

Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
Correlation analysis of KRAS mutation results with clinical data.

Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.

Enrollment

420 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria